JP2020518651A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518651A5
JP2020518651A5 JP2019561277A JP2019561277A JP2020518651A5 JP 2020518651 A5 JP2020518651 A5 JP 2020518651A5 JP 2019561277 A JP2019561277 A JP 2019561277A JP 2019561277 A JP2019561277 A JP 2019561277A JP 2020518651 A5 JP2020518651 A5 JP 2020518651A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
abu
fine particles
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019561277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518651A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031663 external-priority patent/WO2018208829A1/en
Publication of JP2020518651A publication Critical patent/JP2020518651A/ja
Publication of JP2020518651A5 publication Critical patent/JP2020518651A5/ja
Withdrawn legal-status Critical Current

Links

JP2019561277A 2017-05-08 2018-05-08 抗血管新生ペプチドの持続送達のための生分解性微粒子 Withdrawn JP2020518651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502913P 2017-05-08 2017-05-08
US62/502,913 2017-05-08
PCT/US2018/031663 WO2018208829A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Publications (2)

Publication Number Publication Date
JP2020518651A JP2020518651A (ja) 2020-06-25
JP2020518651A5 true JP2020518651A5 (https=) 2021-07-26

Family

ID=64104968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019561277A Withdrawn JP2020518651A (ja) 2017-05-08 2018-05-08 抗血管新生ペプチドの持続送達のための生分解性微粒子

Country Status (8)

Country Link
US (1) US20200179285A1 (https=)
EP (1) EP3621597A4 (https=)
JP (1) JP2020518651A (https=)
KR (1) KR20200003859A (https=)
CN (1) CN111315364A (https=)
AU (1) AU2018266690A1 (https=)
CA (1) CA3063140A1 (https=)
WO (1) WO2018208829A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021056B1 (pt) 2017-04-06 2022-11-22 Sustain Holdings, Llc Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
AU2020248438A1 (en) 2019-03-26 2021-10-28 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
EP3958889B1 (en) 2019-04-22 2025-01-08 Sustain Holdings, LLC Collagen mimetic peptide compositions for treating a posterior segment ocular disease or disorder involving the retina, retinal blood vessels, retinal nerves or optic nerve
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
US9802984B2 (en) * 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.

Similar Documents

Publication Publication Date Title
JP2020518651A5 (https=)
Ward et al. Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres
JP6700348B2 (ja) 持続型薬物送達インプラント
JP2018500394A5 (https=)
JP2008528446A5 (https=)
ES2782111T3 (es) Micropartículas cargadas con ciclosporina de liberación sostenida
JP2019535651A5 (https=)
US9044436B2 (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
JP2020518651A (ja) 抗血管新生ペプチドの持続送達のための生分解性微粒子
CA2891365A1 (en) Composition for immediate and extended release
CN1638734A (zh) 微粒结膜下给药的药物释放系统
US20150306170A1 (en) Composition for immediate and extended release
CN108697810A (zh) 用于剂的控制释放的聚合物复合材料
JP2025118607A5 (https=)
JPWO2021195163A5 (https=)
RU2409348C2 (ru) Лекарственные составы с контролируемым высвобождением, основанные на блок-сополимерах
RU2476235C2 (ru) Композиции на основе биосовместимых микрочастиц альгиновой кислоты, предназначенные для регулируемого высвобождения активных ингредиентов при внутривенном введении
KR101732609B1 (ko) 생리활성물질의 순차적 방출제어를 위한 고분자 혼합 제제
TWI660740B (zh) 水膠組合物及包含其之藥物傳輸系統
CN107970204B (zh) 水凝胶组合物及包含其的药物递送系统
Karagoz et al. Producing Aflibercept Loaded Poly (Lactic Co Glycolic Acid)[Plga] Nanoparticles As A New Ocular Drug Delivery System and Its Challenges
JPWO2020247625A5 (https=)
CN120267619A (zh) 一种奥氮平长效缓释微球制剂及其制备方法与应用
CN104906587B (zh) 一种膦甲酸钠眼玻璃体腔内缓释药物
CN104958762B (zh) 一种33g针头注射用雷珠单抗眼玻璃体腔内缓释药物